Litcius/Paper detail

Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights

Adélaïde Chesnay, Éric Bailly, Laure Cosson, Thomas Flament, Guillaume Désoubeaux

2022Journal of Cystic Fibrosis19 citationsDOIOpen Access PDF

Topics & Concepts

Allergic bronchopulmonary aspergillosisIvacaftorCystic fibrosisMedicineAspergillusCystic fibrosis transmembrane conductance regulatorImmunologyAspergillosisAllergyInternal medicineMicrobiologyBiologyImmunoglobulin EAntibodyCystic Fibrosis Research AdvancesAsthma and respiratory diseasesTracheal and airway disorders
Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights | Litcius